Stock Scorer
Stock Board CompareNew Screen
Donate
…
Report Measures Companies
Sign in

Anbio Biotechnology (NNNN)

Every figure this model derived for NNNN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 11,901,231 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 30,242,859 AssetsCurrent 2025-12-31
current liabilities 87,836 LiabilitiesCurrent 2025-12-31
equity 30,155,023 StockholdersEquity 2025-12-31
ocf -6,739,075 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 8,646,844 RevenueFromContractWithCustomerIncludingAssessedTax 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up NNNN on one particular measure came for.

RatioValue
cash operating margin66.7
current ratio344.31
current ratio reported344.31
dilution pct3.27
ebit cagr-17.29
ebit yoy189.06
ev ebit24.97
ev owner earnings-21.37
ev sales16.65
fcf margin-77.94
operating margin66.7
owner earnings margin-77.94
revenue growth5.64
revenue growth per share2.3
roic24.96
rule of 4072.34
sbc pct revenue0.0

Everything else this filing tags

72 more elements from NNNN's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.

ElementNewestAs of PeriodsUnit
WeightedAverageNumberOfSharesOutstandingBasic43,672,0222025-12-31 6shares
WeightedAverageNumberOfDilutedSharesOutstanding43,672,0222025-12-31 3shares
ProceedsFromSaleAndMaturityOfMarketableSecurities35,803,3362024-12-31 3USD
PaymentsToAcquireMarketableSecurities35,466,2352024-12-31 3USD
Assets30,242,8592025-12-31 4USD
LiabilitiesAndStockholdersEquity30,242,8592025-12-31 4USD
RetainedEarningsAccumulatedDeficit23,577,0042025-12-31 4USD
PaymentsToAcquireShortTermInvestments19,420,0002025-12-31 3USD
ProceedsFromSaleOfShortTermInvestments15,217,5042025-12-31 3USD
OtherAssetsCurrent14,078,5922025-12-31 2USD
Revenues8,646,8442025-12-31 6USD
IncreaseDecreaseInPrepaidExpensesOther8,395,5072025-12-31 6USD
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents7,766,7382025-12-31 8USD
GrossProfit7,543,1622025-12-31 6USD
CashUninsuredAmount7,347,8612025-12-31 4USD
ProceedsFromIssuanceOfCommonStock7,230,0002025-12-31 3USD
NetCashProvidedByUsedInFinancingActivities6,947,4502025-12-31 5USD
AdditionalPaidInCapitalCommonStock6,563,6302025-12-31 4USD
StockIssuedDuringPeriodValueNewIssues6,560,0102025-12-31 3USD
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest6,403,4632025-12-31 6USD
NetIncomeLoss6,403,4632025-12-31 6USD
OperatingIncomeLoss5,767,7402025-12-31 6USD
NetCashProvidedByUsedInInvestingActivities-4,202,4962025-12-31 6USD
ShortTermInvestments4,134,4932025-12-31 2USD
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3,994,1212025-12-31 6USD
AccountsReceivableGrossCurrent3,655,9642025-12-31 4USD
AccountsReceivableNetCurrent3,655,9642025-12-31 4USD
IncreaseDecreaseInAccountsReceivable2,591,1702025-12-31 6USD
OperatingExpenses1,775,4222025-12-31 6USD
IncreaseDecreaseInAccountsPayable-1,625,2552025-12-31 6USD
SellingGeneralAndAdministrativeExpense1,574,1172025-12-31 6USD
CostOfRevenue1,103,6822025-12-31 6USD
NonoperatingIncomeExpense635,7232025-12-31 6USD
PrepaidExpenseAndOtherAssetsCurrent607,0722025-12-31 4USD
PrepaidExpenseCurrent606,1242025-12-31 4USD
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets581,4662025-12-31 6USD
CashFDICInsuredAmount500,0002025-12-31 2HKD
ForeignCurrencyTransactionGainLossBeforeTax493,5622025-12-31 6USD
DeferredOfferingCosts387,4402024-12-31 1USD
IncreaseDecreaseInInventories-353,8722023-12-31 3USD
InterestIncomeOther337,1012024-12-31 3USD
PaymentsOfStockIssuanceCosts282,5502025-12-31 5USD
FederalDepositInsuranceCorporationPremiumExpense250,0002025-12-31 1USD
ResearchAndDevelopmentExpense201,3052025-12-31 6USD
InvestmentIncomeInterest142,0232025-12-31 6USD
AccountsPayableOtherCurrent104,9792024-12-31 2USD
AccruedPayrollTaxesCurrent87,8362025-12-31 3USD
Liabilities87,8362025-12-31 4USD
OtherLiabilitiesCurrent87,8362025-12-31 4USD
RealizedInvestmentGainsLosses-68,0032025-12-31 6USD
CashFDICInsuredAmount64,0002025-12-31 2USD
OtherPrepaidExpenseCurrent24,3122024-12-31 2USD
IncreaseDecreaseInOperatingLeaseLiability-18,3112022-12-31 1USD
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability18,3112022-12-31 1USD
OtherReceivableAfterAllowanceForCreditLossNoncurrent18,0092023-12-31 1USD
IncreaseDecreaseInOtherCurrentLiabilities-17,1432025-12-31 6USD
OperatingLeaseRightOfUseAssetAmortizationExpense12,0592023-12-31 3USD
StockIssuedDuringPeriodValueOther10,0002023-12-31 2USD
DepositsAssetsCurrent1,2942024-12-31 2USD
DepositsAssetsNoncurrent1,2932023-12-31 1USD
OtherReceivablesNetCurrent9482025-12-31 2USD
OtherNonoperatingIncome1382025-12-31 6USD
NumberOfOperatingSegments12024-12-31 1pure
NumberOfOperatingSegments12025-12-31 1segment
EarningsPerShareBasic02025-12-31 6USD/shares
EarningsPerShareDiluted02025-12-31 6USD/shares
AccountsPayableCurrent02025-12-31 4USD
DeferredCosts02025-12-31 4USD
IncreaseDecreaseInDepositOtherAssets02025-12-31 6USD
AllowanceForDoubtfulAccountsReceivableCurrent02025-12-31 2USD
IncomeTaxExpenseBenefit02025-12-31 3USD
StockIssuedDuringPeriodValueShareBasedCompensationForfeited02023-12-31 1USD

What to be careful about

What this model itself distrusts about NNNN's figures. Written by the derivation as it ran, not added afterwards.